Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher
Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.
Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher
Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.
Progress
48% Bias Score
Stock Splits Surge: BofA Predicts Market-Beating Returns
Bank of America predicts a surge in stock splits, exceeding a decade-long trend, with companies like Netflix, Meta Platforms, and Eli Lilly as prime candidates; this could significantly boost returns for investors, exceeding average market performance.
Stock Splits Surge: BofA Predicts Market-Beating Returns
Bank of America predicts a surge in stock splits, exceeding a decade-long trend, with companies like Netflix, Meta Platforms, and Eli Lilly as prime candidates; this could significantly boost returns for investors, exceeding average market performance.
Progress
48% Bias Score
Eli Lilly Stock Tumbles Despite Positive 2025 Outlook
Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...
Eli Lilly Stock Tumbles Despite Positive 2025 Outlook
Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...
Progress
40% Bias Score
Eli Lilly Stock Soars on Obesity Drug Success
Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...
Eli Lilly Stock Soars on Obesity Drug Success
Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...
Progress
48% Bias Score
FDA Approves First Prescription Sleep Apnea Drug: Zepbound
The Food and Drug Administration (FDA) approved Zepbound, a drug previously approved for weight loss, as the first prescription medication to treat sleep apnea, affecting an estimated 39 million American adults.
FDA Approves First Prescription Sleep Apnea Drug: Zepbound
The Food and Drug Administration (FDA) approved Zepbound, a drug previously approved for weight loss, as the first prescription medication to treat sleep apnea, affecting an estimated 39 million American adults.
Progress
36% Bias Score
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments
Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.
Progress
36% Bias Score
Cramer's Trust Adjusts Portfolio: Sells Coterra, Honeywell; Buys Eli Lilly
Jim Cramer's Charitable Trust will sell 200 shares of Coterra Energy, 45 shares of Honeywell, and buy 10 shares of Eli Lilly on Tuesday, adjusting its portfolio weighting based on profit-taking, fundamental concerns, and long-term growth prospects.
Cramer's Trust Adjusts Portfolio: Sells Coterra, Honeywell; Buys Eli Lilly
Jim Cramer's Charitable Trust will sell 200 shares of Coterra Energy, 45 shares of Honeywell, and buy 10 shares of Eli Lilly on Tuesday, adjusting its portfolio weighting based on profit-taking, fundamental concerns, and long-term growth prospects.
Progress
36% Bias Score
Zepbound Poised to Exacerbate Healthcare Cost Increases
Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...
Zepbound Poised to Exacerbate Healthcare Cost Increases
Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...
Progress
40% Bias Score
FDA Approves Zepbound for Obstructive Sleep Apnea
The FDA approved Eli Lilly's Zepbound for treating obstructive sleep apnea (OSA), expanding its use beyond obesity; clinical trials showed 43-51.5% disease resolution in patients compared to 13.6-14.9% with placebo, potentially impacting 80 million Americans with OSA.
FDA Approves Zepbound for Obstructive Sleep Apnea
The FDA approved Eli Lilly's Zepbound for treating obstructive sleep apnea (OSA), expanding its use beyond obesity; clinical trials showed 43-51.5% disease resolution in patients compared to 13.6-14.9% with placebo, potentially impacting 80 million Americans with OSA.
Progress
56% Bias Score
Eli Lilly Stock Rebounds After Initial Post-Election Dip
Post-election, Eli Lilly's stock initially fell 6% due to concerns over President-elect Trump's choice for Health and Human Services, but has since rebounded due to meetings between Eli Lilly's CEO and the President-elect, coupled with Elon Musk's public support for affordable weight-loss drugs, ind...
Eli Lilly Stock Rebounds After Initial Post-Election Dip
Post-election, Eli Lilly's stock initially fell 6% due to concerns over President-elect Trump's choice for Health and Human Services, but has since rebounded due to meetings between Eli Lilly's CEO and the President-elect, coupled with Elon Musk's public support for affordable weight-loss drugs, ind...
Progress
44% Bias Score